MBX Biosciences, Inc. (NYSE:MBX) Director Purchases $468,844.74 in Stock

MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 47,502 shares of MBX Biosciences stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $9.87 per share, with a total value of $468,844.74. Following the transaction, the director now directly owns 3,205,930 shares of the company's stock, valued at $31,642,529.10. This represents a 1.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

MBX Biosciences Price Performance

Shares of MBX stock traded down $0.84 on Friday, reaching $11.00. The stock had a trading volume of 86,797 shares, compared to its average volume of 308,918. MBX Biosciences, Inc. has a 1 year low of $8.63 and a 1 year high of $27.50. The stock's 50 day simple moving average is $14.05.

Institutional Trading of MBX Biosciences

Several institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in MBX Biosciences during the 4th quarter valued at approximately $27,000. Virtus ETF Advisers LLC purchased a new position in MBX Biosciences during the fourth quarter valued at $64,000. The Manufacturers Life Insurance Company grew its position in MBX Biosciences by 7.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 49,675 shares of the company's stock worth $916,000 after acquiring an additional 3,481 shares in the last quarter. Deutsche Bank AG purchased a new stake in MBX Biosciences during the fourth quarter valued at approximately $80,000. Finally, Corebridge Financial Inc. bought a new stake in shares of MBX Biosciences in the 4th quarter valued at approximately $103,000.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.